source
- Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trialInhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
- UnitedHealth executives donate heavily to Rep. Katherine Clark as No Surprises Act debate intensifiesUnitedHealth Group's senior leadership, including CEO Stephen Hemsley, recently made sizable campaign contributions to Rep. Katherine Clark of Massachusetts. Clark, the House Democratic leader who…